Name of company
Place of incorporation
Date of incorporation
Percentage of ownership by the Group
Principal activities
BeyondSpring Pharmaceuticals Inc. (“BeyondSpring US”)
Delaware, U.S.
June 18, 2013
100%
Clinical trial activities
BeyondSpring Ltd.
The British Virgin Islands (“BVI”)
December 3, 2014
Holding company
BeyondSpring (HK) Limited (“BeyondSpring HK”)
Hong Kong
January 13, 2015
Wanchun Biotechnology Limited (“BVI Biotech”)
BVI
April 1, 2015
Wanchun Biotechnology (Dalian) Ltd. (“Wanchun Dalian”)
People’s Republic of China (“PRC”)
April 23, 2015
Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”)
PRC
May 6, 2015
57.97%
Beijing Wanchun Pharmaceutical Technology Ltd. (“Beijing Wanchun”)
May 21, 2018
SEED Therapeutics Inc. (“SEED”)
June 25, 2019
36.51%
Pre-clinical development activities
SEED Technology Limited (“SEED Technology”)
December 9, 2019
SEED Therapeutics US, Inc. (“SEED US”)
November 25, 2020
Wanchun Hongji (Dalian) Pharmaceuticals Ltd. (“Wanchun Hongji”)
March 22, 2022
SEED LH Inc.
September 30, 2025
SEED LH MG Inc.
October 6, 2025
Product development activities
A tabular disclosure of ownership percentage of subsidiaries of the company.
No definition available.